Global Roundup: Denmark's Ascendis Sees "Real Control" in Hypothyroidism
At ENDO 2022, Ascendis will share Phase II and III data showing clinical efficacy for its investigational product candidate for hypoparathyroidism. For this and more, see inside.
Source: biospace.com